Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Multiple Myeloma 18Hodgkin Disease 10Recurrence 8Lymphoma, Large B-Cell, Diffuse 8Lymphoma 8Leukemia, Myeloid, Acute 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Non-Hodgkin 7Breast Neoplasms 7Myelodysplastic Syndromes 6Lymphoma, Mantle-Cell 5Leukemia, Lymphocytic, Chronic, B-Cell 5Carcinoma, Non-Small-Cell Lung 5Waldenstrom Macroglobulinemia 4Neoplasms 4Melanoma 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, Extranodal NK-T-Cell 4Leukemia 4Immunoblastic Lymphadenopathy 4Glioma 4Sezary Syndrome 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Mycosis Fungoides 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Diffuse Intrinsic Pontine Glioma 3Burkitt Lymphoma 3Solid Tumors 2

Interventions

lutetium Lu 177 dotatate 29Everolimus 19Temozolomide 11gallium Ga 68 dotatate 10Nivolumab 10Magnetic Resonance Spectroscopy 10Capecitabine 9pembrolizumab 8lanreotide 8Positron Emission Tomography Computed Tomography 8cabozantinib 73-Iodobenzylguanidine 7177Lu-octreotide, DOTA(0)-Tyr(3)- 7Somatostatin 690Y-octreotide, DOTA-Tyr(3)- 6telotristat ethyl 5lenvatinib 5Octreotide 5Lutetium-177 5Ga(III)-DOTATOC 5Fluorodeoxyglucose F18 5Carboplatin 5avelumab 4Positron-Emission Tomography 4Ipilimumab 4Bevacizumab 4surufatinib 3pasireotide 3fluorodopa F 18 3copper dotatate CU-64 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neuroendocrine Tumors × Panobinostat × Clear all
NCT00985946 2019-12-09

Study of Panobinostat in Patients With Neuroendocrine Tumors

University of Wisconsin, Madison

Phase 2 Terminated
15 enrolled 11 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡